Experts from Perceptive Informatics will discuss these enhanced
capabilities at Booth #333 in the exhibit hall during the Alzheimer's
Association 2009 International Conference on Alzheimer's Disease
(ICAD), to be held
'With CNS and oncology research growing at a fast pace, Perceptive
Informatics is focused on expanding its capabilities to help clients
use medical imaging as an endpoint, or biomarker, to assess efficacy
and safety of new treatments in these important therapeutic areas,'
said
According to
Biospective supplements the medical imaging capabilities of Perceptive Informatics by providing software solutions tailored for CNS and oncology studies, including specialized Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) techniques. The Medical Imaging Group of Perceptive Informatics offers a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology imaging.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, medical communications and
consulting services to the worldwide pharmaceutical, biotechnology and
medical device industries. Committed to providing solutions that
expedite time-to-market and peak-market penetration, PAREXEL has
developed significant expertise across the development and
commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical trials management,
medical education and reimbursement. Perceptive Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions,
including medical imaging, to facilitate the clinical development
process. Headquartered near
This release contains 'forward-looking' statements regarding future
results and events. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the words
'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'appears,'
'estimates,' 'projects,' 'targets,' and similar expressions are also
intended to identify forward-looking statements. The forward-looking
statements in this release involve a number of risks and uncertainties.
The Company's actual future results may differ significantly from the
results discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference include,
but are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating improvements
resulting from recent restructurings; the loss, modification, or delay
of contracts which would, among other things, adversely impact the
Company's recognition of revenue included in backlog; the Company's
dependence on certain industries and clients; the Company's ability to
win new business, manage growth and costs, and attract and retain
employees; the Company's ability to complete additional acquisitions
and to integrate newly acquired businesses or enter into new lines of
business, including, but not limited to, the successful business
integration and anticipated synergy achievements in connection with the
ClinPhone acquisition; the impact on the Company's business of
government regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties; the
potential adverse impact of health care reform; and the effects of
exchange rate fluctuations and other international economic, political,
and other risks. Such factors and others are discussed more fully in
the section entitled 'Risk Factors' of the Company's Quarterly Report
on Form 10-Q for the quarter ended
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Contacts:
Jennifer Baird, Senior Director of Public Relations
PAREXEL International
Tel: +781-434-4409
Jennifer.Baird@PAREXEL.com
Rebecca Passo
SHIFT Communications
Tel: +617-779-1817
Email: rpasso@shiftcomm.com
SOURCE PAREXEL International Corporation